Coinbase Global, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Coinbase Global, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.18B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $6.56B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $3.11B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $3.19B | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $7.84B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $1.28B | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $533.74M | Feb 25, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.26B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $2.58B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $94.87M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | ($2.62B) | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $3.62B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $322.32M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | ($30.39M) | Feb 25, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.44B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $2.31B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | ($161.66M) | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | ($2.71B) | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $3.08B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $408.95M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | ($45.78M) | Feb 25, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.67B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $1.47B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $1.32B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $2.33B | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $1.29B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $271.73M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $185.04M | Feb 25, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.43B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $3.10B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $673.38M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | ($1.59B) | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $4.04B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $293.55M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | ($80.59M) | Feb 25, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $2.93M | Feb 21, 2023 |
| FY2022 | Dec 31, 2021 | $2.91M | Feb 21, 2023 |
| FY2022 | Dec 31, 2020 | $9.91M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $33.52M | Feb 25, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $29.67B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $22.54B | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $14.75B | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $89.72B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $21.27B | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $5.86B | Feb 25, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.88B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $12.27B | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $8.47B | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $84.27B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $14.89B | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $4.33B | Feb 25, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.79B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $10.28B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $6.28B | Feb 12, 2026 |
| FY2025 | Dec 31, 2022 | $5.45B | Feb 12, 2026 |
| FY2024 | Dec 31, 2021 | $6.38B | Feb 13, 2025 |
| FY2023 | Dec 31, 2020 | $963.58M | Feb 15, 2024 |
| FY2022 | Dec 31, 2019 | $497.09M | Feb 21, 2023 |
| FY2021 | Dec 31, 2018 | $500.07M | Feb 25, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.17B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $1.14B | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $1.14B | Feb 13, 2025 |
| FY2024 | Dec 31, 2022 | $1.07B | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $625.76M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $77.21M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $54.70M | Feb 25, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.22B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $4.96B | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $1.82B | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $1.73B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $4.35B | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $726.30M | Feb 25, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.29B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $9.31B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $5.49B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $4.43B | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $7.12B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $1.06B | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $548.95M | Feb 25, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.21B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $4.23B | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $2.98B | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $3.39B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $3.38B | Feb 21, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4 | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | 10 | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | (11) | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | 17 | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | 1 | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Feb 25, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4 | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | 9 | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | (11) | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | 14 | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | 1 | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Feb 25, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 267.84M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | 253.64M | Feb 12, 2026 |